Suspensions

We develop suspensions prioritizing uniformity, stability, and scalable processes that ensure redispersion.

Inner banner
Uniform dose delivery 

Stable suspension performance

Suspension drug products succeed when dose uniformity and physical stability stay under control as requirements increase. Groupe PARIMA supports non-sterile oral, nasal, otic, and topical suspensions with scalable processes and proactive formulation risk management, helping customers keep product performance consistent from development through manufacturing.

Predictable batch outcomes

We reduce settling, redispersibility, and dose variability risks by linking formulation design, in‑house analytical support, and reproducible manufacturing to maintain stable, scalable, and predictable suspensions.

DOSE UNIFORMITY YOU CAN TRUST

Focus on controlling particle behavior and dispersion so each dose remains consistent, even as batch size grows.

PHYSICAL STABILITY THAT HOLDS

Address settling risk and redispersibility early with formulation and stability designed to confirm long-term performance.

PACKAGING THAT SUPPORTS REAL USE

Evaluate packaging compatibility that supports consistent dosing, product stability, and user experience.

Reliable product behavior

We design suspension products around particle behavior, reproducible processing, and fit-for-purpose testing so dose uniformity and stability remain predictable.

Card 01

SET TARGET PARTICLE BEHAVIOR

We define the particle size intent and performance targets that will drive homogeneity, uniformity, dosing consistency, and overall suspension performance.

Card 02

ENGINEER DISPERSION AND RHEOLOGY

We select and tune excipients and process conditions to maintain even particle distribution, balancing viscosity and handling to keep manufacturing and use practical.

Card 03

PROVE REDISPERSION AND DOSE UNIFORMITY

We confirm that the product stays dose-consistent over time, and redispersibility with testing designed to reflect real use and real shelf-life conditions.

Card 04

LOCK A REPRODUCIBLE SCALE-UP PATH

We translate the formulation into a scalable process by controlling steps that change with volume, then support it with in‑house analytical work and microbial testing.

Card 05

VALIDATE PRESENTATION AND PACKAGING FIT

We evaluate packaging and delivery early, including options that support consistent dosing and stability during storage, shipping, and routine handling.

Our Capabilities

We design suspension programs around particle behavior, dose uniformity, and packaging fit from the start.

Otic Suspensions
Otic Suspensions

Support localized delivery with dependable dosing. We fine-tune formulation and processing to keep particle distribution consistent, confirm packaging fit early, and support microbial control.

  • Establishing the particle size range to support consistent dispersion and reliable delivery in the ear.
  • Selecting excipients that support residence time, patient comfort, and preservative compatibility.
  • Supporting consistent dosing through early packaging and delivery-fit evaluation, with shake-before-use verification when applicable.
Nasal Suspensions
Nasal Suspensions

Offer a strong pathway when a solution is not the best fit. We focus on consistent dosing through the device, including spray performance checks and formulation choices that support stability and microbial integrity.

  • Establishing the particle size range to support targeted deposition and consistent spray delivery.
  • Selecting excipients that support mucosal retention, comfortable delivery, and preservative compatibility.
  • Confirming dose uniformity through device-focused checks, including shake-before-use verification and spray pattern testing.
Topical Suspensions
Topical Suspensions

Perform best when formulation and packaging work as one system. We confirm delivery-fit early, from applicators to agitation-assisted bottles, supporting consistent dosing, stable performance, and a smooth user experience.

  • Maintain physical stability of APIs that tend to aggregate or crystallize.
  • Ensure even distribution of active particles throughout the product.
  • Select and test film-forming agents, emollients, or penetration enhancers as needed.
  • Evaluate in vitro release and particle mobility to optimize drug delivery performance.
Oral Suspensions
Oral Suspensions

Well-suited for pediatric, geriatric, and dose-titration programs where flexible administration is important. We establish viscosity and density so the product pours smoothly and maintains consistent performance over shelf life.

  • Optimize particle size to improve sedimentation behavior and enhance bioavailability.
  • Select and tailor suspending agents (cellulose derivatives, gums, clays) to ensure redispersibility and dose uniformity.
  • Engineer palatability solutions through advanced, multi-layered taste-masking strategies.
  • Validate preservative efficacy in aqueous, multi-dose formulations to ensure microbial stability.
  • Execute ICH-compliant stability studies, including shake tests and sedimentation kinetics, to confirm long-term product performance.

Our Services

We connect development, analytical support, and GMP execution to ensure suspension uniformity and physical stability.

01
Layer_1 (3)-1
Product Development

Formulate and refine suspensions to support dose uniformity, stable performance, and scale-up readiness.

02
Icons (1)-2
Analytical Services

Use fit‑for‑purpose testing to confirm uniformity and stability, supported by in‑house particle and microbiology capabilities.

03
Icons (2)-1
Manufacturing & Packaging

Deliver scalable suspension manufacturing and packaging with early packaging and device verification to support reliable use.

We make suspension dosing predictable through early control of particle behavior and confirmed stability over time.

Resources

Access practical content to help you plan suspension development and manufacturing with clarity.

Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development
Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development

Contact Us

Develop suspensions with confidence. 

Share your product details, and we'll help align formulation, testing, and execution to maintain consistency from development to commercial supply.